Veteran Roche cancer executive O'Day to lead Gilead

Daniel O’Day will inherit a pile of cash and a company that is looking beyond infectious disease to carve out its space in cancer and build on its newly acquired CAR T platform when he becomes chairman and CEO of Gilead Sciences Inc. (NASDAQ:GILD) next spring.

Genentech Inc. CEO Bill Anderson will succeed O’Day as CEO of the Roche (SIX:ROG; OTCQX:RHHBY) pharmaceuticals division on Jan. 1.

Read the full 654 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE